SCHEMBL368761

SCHEMBL368761

CC(C)(C)OC(=O)N1CCC2(CCC(O)CO2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RECQL P46063 1/20 0.44
HPGD P15428 1/20 0.43
EPHX1 P07099 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
EPHX2 P34913 1/20 0.39
GPR119 Q8TDV5 4/20 0.39
MGLL Q99685 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
PTPN2 P17706 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPN6 P29350 1/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20411385 0.87 USP2 (0.46) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL20411386 0.87 USP2 (0.46) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL897951 0.87 USP2 (0.46) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL21636211 0.85 USP2 (0.44) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL30864016 0.85 USP2 (0.44) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL16465364 0.83 NR1H2 (0.47) USP2SMN1; SMN2RECQLHPGDGPR119
SCHEMBL17125240 0.83 GPR119 (0.43) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL20395941 0.82 USP2 (0.40) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL15776899 0.82 USP2 (0.41) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL16466158 0.82 RECQL (0.43) USP2SMN1; SMN2RECQLHPGDEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235363-A1 CYCLIN-DEPENDENT KINASE 4 DEGRADERS BLUEPRINT MEDICINES CORPORATION (US) 2025-11-13 WO disclosed
WO-2012009217-A1 SPIROCYCLIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed
EP-1286967-B1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME (GB) 2006-09-27 EP disclosed
US-7105507-B2 Cyclohexane derivatives and their use as therapeutic agents MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20030236250-A1 Cyclohexane derivatives and their use as therapeutic agents MERCK SHARP & DOHME LTD. (GB) 2003-12-25 US disclosed
EP-1286967-A1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 2003-03-05 EP disclosed
WO-2001087838-A1 CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236250-A1 Cyclohexane derivatives and their use as therapeutic agents CNR2, CNR1, HTR1A USP2 4091/4885SMN1; SMN2 3052/4885RECQL 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.